drugset / Trial / NCT06453668
A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.
Timeline
- Start
- 2024-04-16
- Primary completion
- 2026-07-02
- Completion
- 2026-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | — | — |